Key result
Aspirin has historically provided small-to-modest cardiovascular benefits for primary prevention in high-risk patients, albeit with an increased risk of bleeding.
Why the study?
Should aspirin be used for primary prevention of cardiovascular events in the post-statin era?
Should aspirin be used for primary prevention of cardiovascular events in the post-statin era?
This article discusses the evolving risk-benefit ratio of aspirin for primary cardiovascular prevention in the modern era of statin therapy.
Between 1853 and 1897, German chemists learned to efficiently combine sodium salicylate with acetyl chloride to produce acetylsalicylic acid. That compound, trademarked as aspirin, proved to be a remarkable antiinflammatory and antithrombotic agent and one of the most widely used drugs in pharmaceutical history. As the medical community’s understanding of platelet biology and atherothrombosis evolved, it became clear that aspirin was highly effective in the secondary prevention of cardiovascular events. Subsequent large-scale primary prevention trials, including the Physicians’ Health Study and the Women’s Health Study, provided evidence of small-to-modest cardiovascular benefits in high-risk patients, albeit with an increased risk of . . .
No takes yet. Share an insight, caveat, or question.
Paul M. Ridker (2018) conducted an editorial in Cardiovascular events. Aspirin was evaluated. Aspirin has historically provided small-to-modest cardiovascular benefits for primary prevention in high-risk patients, albeit with an increased risk of bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: